Insulin Degludec Now FDA-Approved for Type 1 and Type 2 Diabetes
On September 25th, the FDA approved Tresiba (insulin degludec / Novo Nordisk), making it the first new basal insulin to be approved in ten years. This is a once-daily, long acting basal insulin. The half-life is 25 hrs and it is active for up to 42 hours. One benefit of Tresiba is that the patient is not required to take it at the same time every day, although “patients are still encouraged to take it around the same time every day”. The approval was based on two clinical trial programs – BEGIN, which showed non-inferiority to comparators in A1c reduction, and DEVOTE, the cardiovascular safety program. Read the press release from Novo and additional information about Tresiba: www.tresibapro.com.
Posted on July 31, 2020
Posted on July 30, 2020